Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids

Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis biologic. In Part 2 we cover:

4. Viridian Therapeutics — Lumvoa (veligrotug) for thyroid eye disease, active and chronic (FDA approval)

5. Otsuka Pharmaceutical — centanafadine for adult ADHD with comorbid anxiety (Phase 3b)

6. AbbVie — Skyrizi (risankizumab) for pediatric plaque psoriasis and psoriatic arthritis (FDA approval)

The biggest story in Part 2: Lumvoa is only the second IGF-1 receptor antibody ever approved for thyroid eye disease, but it has a much broader label than its predecessor — covering both the active early form and the chronic long-standing form that affects far more patients. For people who've lived with bulging eyes and double vision for years and were told nothing could help, this approval is genuinely new ground.

Catch Part 1 if you missed it. Subscribe at TrialBreaks.com.

#biomedicine #clinicaltrials #science #ophthalmology #thyroideyedisease #ADHD #anxiety #mentalhealth #dermatology #psoriasis #pediatrics #immunology #FDAapproval #autoimmune #IL23